Harrow price target raised to $64 from $54 at Craig-Hallum

Craig-Hallum analyst Chase Knickerbocker raised the firm’s price target on Harrow (HROW) to $64 from $54 and keeps a Buy rating on the shares as the firm added ophthalmic biosimilars, Byooviz and Opuviz, to its model. Craig-Hallum notes that these biosimilars are underappreciated in the Harrow story and says it expects material revenue contributions beginning in 2026. Specific commercial strategies are unclear, with the firm expecting more commentary on the September 26 analyst day.